Elevation Oncology Acquired After Ending Partnership with CSPCCSPCElevation Oncology has been acquired by Concentra Biosciences after halting its Claudin18.2 ADC program with CSPC. The deal includes a $22M valuation and future rights tied to EO-1022, its sole remaining HER3-targeted ADC candidate.
Over $2 Billion! AstraZeneca Partners with CSPC Pharmaceutical GroupAstraZenecaCSPC Pharmaceutical Group (1093.HK) has signed an exclusive licensing agreement with AstraZeneca to globally develop and commercialize CSPC's Lp(a) inhibitor, YS2302018. The deal includes a $100M upfront payment, with potential milestones up to $1.92B plus royalties.